91Ï㽶ÊÓƵ

Abstract: Pulmonary drug delivery is no longer limited to asthma and COPD. The field now spans hundreds of active programs, many led by emerging biotechs that must make early, high-impact decisions with limited data.

Abstract: Selling CDMO services is a complex task that calls for broad skill and technical depth.

Summary:​ Drug development today is shaped by 2 forces: the technical challenge of formulating complex molecules and the external challenge of navigating unstable global supply chains.

91Ï㽶ÊÓƵ’s micronization services help innovators overcome the toughest drug development challenges.

A clinical-stage biotech focused on neurology faced challenges with a lipophilic, oxidation-sensitive molecule limited by solubility, stability, and scalability.

Vinorelbine, a chemotherapy agent traditionally given by IV infusion, was reformulated into the first approved oral softgel capsule through a collaboration between Pierre Fabre and 91Ï㽶ÊÓƵ.

Summary: Late-stage scaling of spray drying for inhaled formulations can result in avoidable delays, post-approval issues, and cost overruns.

Bringing complex oral drugs to the clinic requires overcoming significant solubility, permeability, and bioavailability challenges.

Summary: Pharmaceutical innovators face growing pressure to overcome solubility, permeability, and bioavailability challenges, especially for complex, poorly soluble molecules.

Summary: Early clinical trials are becoming more complex as sponsors face rising regulatory requirements and the challenges of developing advanced drug candidates.